medcelerator · clinician one-pager
New Pill for a Rare Gene-Related Lung Cancer
Jideytro (zidesamtinib) — oral ROS1 kinase inhibitor after a prior ROS1 TKI
FDA Approved · United States · September 7, 2026
Condition: Non-Small Cell Lung Cancer
Who this is for
Jideytro is a US-labelled oral pill for adults whose ROS1-positive lung cancer has already been treated with another ROS1 kinase inhibitor. It may help when resistance mutations, brain metastases, or limited options after prior TKIs are the practical problem. The route today is a US oncology prescription at 100 mg once daily — not a DIY import, and not a confirmed licence outside the United States.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220185s000lbl.pdf
United States · Recruiting clinical trial
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Tests this treatment. Zidesamtinib in ROS1+ NSCLC (ARROS-1, phase 1/2).
https://clinicaltrials.gov/study/NCT05118789
See 1 trial on ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=ROS1&intr=zidesamtinib&aggFilters=status:rec
Possible routes (not confirmed)
Company expanded-access programme · Applicability unknown
Nuvalent expanded access NCT06797362 (ROS1+ NSCLC after ≥1 ROS1 TKI)
EAP sites are in AU, BE, CA, FR, IT, NL, SG, ES, TW and the UK, none in the US (the article's only country); last verified 2026-01.
https://clinicaltrials.gov/study/NCT06797362
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/jideytro-zidesamtinib